Cited by 183Liver Disease and TransplantationMesenchymal stem cell researchLiver physiology and pathology

Human fetal liver derived stem cell transplantation as supportive modality in the management of end stage decompensated liver cirrhosis

Open access
Khan, Aleem A., Shaik, Mahaboob V, Parveen, N., Rajendraprasad, A., Aleem, Mohammed A, Aejaz, M., Srinivas, G., Avinash, T. +5 more·2010·Cell Transplantation

Abstract

Liver transplantation is the only existing modality for treating decompensated liver cirrhosis. Several factors, such as nonavailability of donors, combined with operative risks, complications associated with rejection, usage of immunosuppressive agents, and cost intensiveness, make this strategy available to only a few people. With a tremendous upsurge in the mortality rate of patients with liver disorders worldwide, there is a need to search for an alternative therapeutic tool that can combat the above limitations and serve as a supportive therapy in the management of liver diseases. Cell therapy using human fetal liver-derived stem cells can provide great potential to conservatively manage end-stage liver diseases. Therefore, the present investigation aimed to study and prove the safety and efficacy of human fetal liver-derived stem cell transplantation in patients with end-stage liver cirrhosis. Twenty-five patients with liver cirrhosis of different etiologies were infused with human fetal liver-derived stem cells (EpCAM+ve) labeled with Tc-HMPAO through hepatic artery. Our high throughput analysis using flow cytometry, RT-PCR, and cellular characterization exemplifies fetal liver cells with their high proliferation rate could be the best source for rejuvenating the diseased liver. Further, no episodes related to hepatic encephalopathy recurred in any of the subjects following hepatic stem cell transplantation. There was marked clinical improvement observed in terms of all clinical and biochemical parameters. Further, there was decrease in mean MELD score (p < 0.01) observed in 6 months follow-up in all patients. Therapy using human fetal liver stem/progenitor cells offers a potentially supportive modality to organ transplantation in the management of liver diseases.

Integrity signals

Registry

Crossref · 10.3727/096368910x498241

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When the proliferation of liver parenchymal cells is hampered, especially in advanced fibrosis, liver progenitor cells may become activated and differentiate into mature hepatocytes and cholangiocytes, thereby facilitating repopulation and improving liver function.

    “When the proliferation of liver parenchymal cells is hampered, especially in advanced fibrosis, LPCs may become activated and differentiate into mature hepatocytes and cholangiocytes, thereby facilitating repopulation and improving liver function [20, 41].”
  • In a clinical trial, 25 patients with MELD scores exceeding 16 who were infused with human fetal liver-derived EpCAM+ liver progenitor cells through the hepatic artery had no procedure-related complications and showed significant improvements in MELD scores and levels of serum ALB, ALP, and bilirubin at six months.

    “In a clinical trial, 25 patients with MELD scores exceeding 16 were infused with human fetal liver-derived EpCAM+ LPCs through the hepatic artery [20]. The six-month follow-up period revealed no complications related to the procedure while demonstrating significant improvements in MELD scores and levels of serum ALB, alkaline phosphatase (ALP), and bilirubin.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Khan, A. A., Shaik, M. V., Parveen, N., Rajendraprasad, A., Aleem, M. A., Aejaz, M., Srinivas, G., Avinash, T., Tiwari, S. K., Kumaresan, K., Venkateswarlu, J., Pande, G., & Habibullah, C.
Affiliations
  • Deccan College of Medical Sciences (IN)
  • Centre for Cellular and Molecular Biology (IN)
Venue
Cell Transplantation
Published
2010
Volume
19
Issue
4
Pages
409-418
ISSN
0963-6897 (ISSN-L)
OpenAlex
W2078785430
Cited by
183
References
35
Citations by year
2026: 1 · 2025: 7 · 2024: 3 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 11 · 2016: 15 · 2015: 12 · 2014: 20 · 2013: 17 · 2012: 18
FWCI
11.70
Type
journal article
Language
en
Open access
Licence
cc-by-sa
Locations
  • Cell Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
stem cell transplantation, decompensated cirrhosis, end-stage liver disease, hepatic artery infusion, hepatic encephalopathy, MELD score, cell therapy, liver regeneration, supportive therapy
MeSH terms
Adult, Flow Cytometry, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Biomarkers, Technetium Tc 99m Exametazime, Stem Cell Transplantation, Fetal Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review